Widya Juwita

Widya Juwita

Auto-generated profile, based on publicly available information

Widya Juwita

Ciputra Hospital, West Jakarta, Jakarta, Indonesia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in Anatomy & Cell Biology
Verified
Journal Article
Open access
PDF file
RMRia Margiana
Ria Margiana
WJWidya Juwita
Widya Juwita
KIKhoirul Ima
Khoirul Ima
ZFZakiyatul Faizah
Zakiyatul Faizah
SSSupardi Supardi
Supardi Supardi
Ria Margiana, Widya Juwita, Khoirul Ima, Zakiyatul Faizah, Supardi Supardi. Anat Cell Biol 2023;56:421-7. https://doi.org/10.5115/acb.23.056

1 July 2025 in Biomolecular and Health Science Journal
Verified
Journal Article
Open access
FPFachry Achmad Prodjokusumo
Fachry Achmad Prodjokusumo
WJWidya Juwita
Widya Juwita
ZFZakiyatul Faizah
Zakiyatul Faizah
PSPetrus Supardi
Petrus Supardi
FAFaisal Yusuf Ashari
Faisal Yusuf Ashari
Introduction: Severe oligozoospermia (<5 million/mL) creates challenges for preserving male fertility. Cryopreservation is essential in such cases but often results in considerable losses of sperm motility and viability due to oxidative and cryogenic damage. Ubiquinone (coenzyme Q10) is a mitochondrial antioxidant and a potential cryoprotective agent; however, its efficacy in cryopreservation of severely oligozoospermic samples remains underexplored. The effects of in vitro ubiquinone supplementation on postthaw sperm motility and viability were examined in men with severe oligozoospermia. Methods: A posttest-only control-group design was used in this laboratory study, with eight semen samples exhibiting severe oligozoospermia. The samples were evenly allocated to control (no supplementation) and treatment (100 µM ubiquinone added to the cryopreservation solution) groups. Motile spermatozoa (10–15 cells/aliquot) were selected via micromanipulation, cryopreserved in Origio™ media, and kept for 24 h. Cell motility and viability postthaw were evaluated microscopically and analyzed using paired t -tests. Results: The postthaw motility of the ubiquinone-treated samples decreased significantly (88.93% ± 7.27%) compared to the control group (98.25% ± 4.95%; P = 0.032). The viability loss in the ubiquinone group (43.50% ± 7.74%) was insignificantly lower than in the control group (47.38% ± 10.47%) ( P = 0.357). Conclusions: In males with severe oligozoospermia, ubiquinone supplementation during cryopreservation decreased postthaw motility loss in sperm, indicating the possibility of employing ubiquinone as a targeted antioxidant adjunct for fertility preservation. However, given the settings of the research, ubiquinone’s impact on cell viability was restricted. To investigate the wider therapeutic uses of ubiquinone in fertility preservation, further research is needed.